Company MEDIGENE NA Swiss Exchange
Equities
OXMDGG
DE0005020903
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
21/05 | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
21/05 | Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term | CI |
Business Summary
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunotherapies
100.0
%
| 31 | 100.0 % | 6 | 100.0 % | -80.69% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Germany
100.0
%
| 25 | 80.4 % | 6 | 100.0 % | -75.97% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Selwyn Ho
CEO | Chief Executive Officer | 53 | 25/22/25 |
Dolores Schendel
CTO | Chief Tech/Sci/R&D Officer | - | 01/14/01 |
Pamela Keck
IRC | Investor Relations Contact | - | 01/23/01 |
Christian Schmid
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 12/16/12 | |
Frank Mathias
BRD | Director/Board Member | 62 | 15/18/15 |
Anthony Man
BRD | Director/Board Member | 68 | 16/20/16 |
Gerd Zettlmeissl
CHM | Chairman | 68 | 01/17/01 |
Ronald Scott
BRD | Director/Board Member | 69 | 01/17/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 29,475,189 | 28,605,076 ( 97.05 %) | 0 | 97.05 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+11.91% | 12TCr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr |
- Stock Market
- Equities
- MDG1 Stock
- OXMDGG Stock
- Company MEDIGENE NA